This is an important point because zolbetuximab is administered intravenously and primarily targets peritoneal invasive cancer tissues with blood supply, and therefore information concerning CLDN18 status in the resected PD tissue samples, not just tumor cells floating in ascites, is needed. The gene discussed is CLDN18; the disease is neoplasm.